A. Cooper

发表

Digoxin net secretory transport in bronchial epithelial cell layers is not exclusively mediated by P-glycoprotein/MDR1.

D. Pritchard, Alan P Brown, C. Bosquillon, 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Evaluation of layers of the rat airway epithelial cell line RL-65 for permeability screening of inhaled drug candidates.

D. Pritchard, C. Bosquillon, C. Hilgendorf, 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors.

Stuart Paine, John Unitt, J. Unitt, 2004, Bioorganic & medicinal chemistry letters.

Prediction of Efficacious Inhalation Lung Doses via the Use of In Silico Lung Retention Quantitative Structure-Activity Relationship Models and In Vitro Potency Screens

Anne Cooper, Tim Potter, Tim Luker, 2010, Drug Metabolism and Disposition.

P-glycoprotein Potentiates CYP3A4-mediated Drug Disappearance during Caco-2 Intestinal Secretory Detoxification

B. Hirst, D. Ford, A. Cooper, 2004, Journal of drug targeting.

Differential Multidrug Resistance-Associated Protein 1 through 6 Isoform Expression and Function in Human Intestinal Epithelial Caco-2 Cells

B. Hirst, A. Cooper, Hannah M Prime-Chapman, 2004, Journal of Pharmacology and Experimental Therapeutics.

Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents.

C. Corrigan, A. B. Kay, A. Cooper, 1996, The European respiratory journal.

Induction of rodent hepatic drug-metabolizing enzyme activities by the novel anticonvulsant remacemide hydrochloride.

C. Logan, R. Riley, A. Cooper, 1995, Drug metabolism and disposition: the biological fate of chemicals.

Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists.

John Unitt, J. Unitt, A. Baxter, 2006, Bioorganic & medicinal chemistry letters.

Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists.

Bryan Roberts, John Unitt, J. Unitt, 2003, Bioorganic & medicinal chemistry letters.

Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin‐converting enzyme, in the rat

R. Carr, D. Robinson, A. Cooper, 1990, British journal of pharmacology.

Excretion and metabolism of tipredane, a novel glucocorticoid, in the rat, mouse, monkey, and human.

C. Logan, A. Cooper, A. Gray, 1996, Drug Metabolism And Disposition.

Optimisation of DMPK by the inhaled route: challenges and approaches.

Ken Grime, Douglas Ferguson, K. Grime, 2012, Current drug metabolism.

Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides.

Simon J Brown, D. Whittaker, J. G. Cumming, 2006, Bioorganic & medicinal chemistry letters.

The discovery of novel, potent and highly selective inhibitors of inducible nitric oxide synthase (iNOS).

Glen Andrews, Paul D Leeson, Anders Åberg, 2011, Bioorganic & medicinal chemistry letters.

Understanding Exposure-Receptor Occupancy Relationships for Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators across a Range of Preclinical and Clinical Studies

K. Bennett, G. Bakker, E. Sergeev, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides.

D. Whittaker, J. G. Cumming, K. Grime, 2005, Bioorganic & medicinal chemistry letters.

The influence of DMPK as an integrated partner in modern drug discovery.

Robert J Riley, R. Riley, Iain J Martin, 2002, Current drug metabolism.